Pfizer’s BRAFTOVI Regimen Shows Significant PFS Benefit in BRAF V600E Colorectal Cancer Trial
Pfizer’s BRAFTOVI regimen showed a statistically significant improvement in progression-free survival in Cohort 3 of the Phase 3 BREAKWATER trial for untreated metastatic colorectal cancer with BRAF V600E mutations. Earlier data demonstrated a 64.4% objective response rate versus 39.2% with standard care (odds ratio 2.76, p=0.001).
1. BREAKWATER Cohort 3 Trial Design
Cohort 3 of the Phase 3 BREAKWATER trial evaluated encorafenib plus cetuximab with FOLFIRI in previously untreated metastatic colorectal cancer patients harboring the BRAF V600E mutation. Patients were randomized to receive the BRAFTOVI regimen versus standard-of-care chemotherapy with or without bevacizumab.
2. Progression-Free Survival Improvement
The BRAFTOVI combination demonstrated a statistically significant improvement in progression-free survival compared with standard therapy, marking a key efficacy milestone for patients with BRAF V600E–mutant metastatic disease.
3. Confirmed Objective Response Rate
In this cohort, the confirmed objective response rate reached 64.4% versus 39.2% for standard care (odds ratio 2.76, p=0.001). Overall BREAKWATER data also showed a 60.9% response rate compared with 40.0% with chemotherapy alone.
4. Market Reaction and Analyst Views
Pfizer shares traded about 3.5% below the 20-day SMA and 5.2% below the 100-day SMA, with a 7.9% year-over-year gain and proximity to the 52-week high. RSI sits at 44.45 (neutral) while MACD remains below its signal line. The stock faces resistance at $27.50 and support at $24.50. Analysts maintain a Hold consensus with an average price target of $29.67—Cantor Fitzgerald and UBS both rate it neutral with targets of $27 and $25, respectively.